**4. Self-renewal signaling in leukemia stem cells**

Self-renewal is a key property of LSCs and its deregulation is responsible for leukemia initiation and progression, which could be targeted for LSC eradication. Several pathways controlling LSC self-renewal have been identified in AML, such as WNT/β-catenin signaling and G protein-coupled receptors including GPR84 and LGR4 [5, 6, 19, 20].

## **4.1 WNT/β-catenin signaling pathway**

β-catenin was first associated with colon cancer almost thirty years ago via its interaction with adenomatous polyposis coli (APC) [21, 22]. It later became evident that the canonical WNT/β-catenin pathway is dysregulated in various cancers, including AML [23, 24]. We and others have demonstrated that aberrant activation of WNT/β-catenin signaling contributes to the transformation of normal HSCs into LSCs [5, 25]. Our studies show that WNT/β-catenin signaling pathway is required for self-renewal of LSCs derived from either normal HSCs or lineage-committed progenitors in AML [5].

The WNT/β-catenin pathway was initially explored in normal HSCs (**Figure 3**). Constitutive activation of β-catenin results in an increase in the number of HSCs *in vitro* [26]. However, *in vivo* studies challenge the *in vitro* observation, where the conditional deletion of β-catenin in adult HSCs does not cause the self-renewal defect in mice [27].

#### **Figure 3.**

*Schematic diagram of the canonical WNT/*β*-catenin signaling pathway. In the OFF state, defined by the absence of a WNT ligand,* β*-catenin is repressed via a destruction complex composed of APC, scaffold protein Axin, glycogen synthase kinase 3 (GSK3) and casein kinase 1 (CK1) that phosphorylates* β*-catenin leading to its proteasomal degradation [28–30]. In the ON state, a WNT ligand binds to the receptor complex consisting of lipoprotein receptor-related proteins 5 and 6 (LRP5/6) and frizzled receptors (FZD), which recruits the destruction complex, leading to inhibition of* β*-catenin phosphorylation and therefore ensuring nuclear translocation and the subsequent accumulation of active* β*-catenin [31].*

**101**

*Self-Renewal Pathways in Acute Myeloid Leukemia Stem Cells*

On the other hand, several lines of evidence including our own have demonstrated the importance of WNT/β-catenin pathway in regulation of LSC self-renewal in AML [5, 25]. Our studies have shown that deletion of β-catenin impairs LSC function and blocks AML progression in mice [5]. β-catenin can promote leukemogenesis through cooperation with homeobox (HOX) oncoproteins in HSCs [5]. Conversely, lack of endogenous β-catenin in lineage-committed progenitors limits the ability of HOX genes to efficiently transform the progenitor cells [5]. Despite the recognized importance, treatments directly targeting WNT/β-catenin pathway have been elusive, mainly due to our limited understanding of precise mechanisms of the pathway and lack of key druggable molecules involved in driving constitutive activation of the pathway. Of note, while aberrant activation of β-catenin frequently occurs in human LSCs [25, 32] and is associated with poor patient outcomes in AML [33], increased expression of WNT proteins has not been observed. This suggests that aberrant activation of WNT/β-catenin signaling in AML may require other developmental

**4.2 G protein-coupled receptors serving as modulators of WNT/β-catenin** 

G protein-coupled receptors (GPCRs) are a large superfamily of cell surface signaling proteins that bind extracellular ligands to transduce signals into cells via heterotrimeric G proteins [20]. GPCRs can act as modulators of WNT/β-catenin signaling and have a critical role in embryonic development and stem cell maintenance [20, 34, 35]. Dysregulation of GPCRs have detrimental consequences including malignant transformation and have emerged as crucial players in promoting

The mechanism of action of GPCRs when stimulated by an appropriate ligand (or agonist) is understood in conjunction with its interaction with the G protein heterotrimer, which contains α, β and γ subunits. Ligands binding to GPCRs stimulate conformational changes within the receptor causing the Gα subunit to exchange bound guanosine diphosphate (GDP) for guanosine-5′-triphosphate (GTP). This step is key to the activation of the G protein as it causes the dissociation between the α subunit and the βγ subunit [36]. Each of the G protein subunits is responsible for several downstream effects. The Gα subunits have been classified into four families: Gαs, Gαq, Gαi/o and Gα12/13 each with a distinct function. Typically, Gαs and Gαi moderate cyclic AMP (cAMP) levels by stimulating or inhibiting adenylyl cyclase respectively [37]. Gα<sup>13</sup> typically activates the Rho family of GTPases and Gαq stimulates phospholipase Cβ (PLCβ), leading to activation of intracellular Ca2+ [20]. The βγ dimer subunits activate downstream signaling partners such as Src, phospholipase C, adenylyl cyclase, phosphodiesterases and ion channels [36]. Aberrant activation of GPCRs has a profound effect on many cellular processes and may ultimately lead to malignant progression. Although therapeutic targeting of GPCR signaling pathways in non-cancer disease is not a new phenomenon, our limited understanding of the role played by these receptors in tumorigenesis has hindered the development of therapeutic

G protein-coupled receptor 84 (GPR84) is often described as a pro-inflammatory

receptor. We have documented a crucial role for GPR84 in sustaining LSC selfrenewal through positive regulation of β-catenin signaling in established AML [19]. Overexpression of GPR84 augments activation of β-catenin and its transcriptional co-factors TCF7L2 and c-FOS, and positively modulates a subset of genes associated

*DOI: http://dx.doi.org/10.5772/intechopen.94379*

signaling molecules that function as agonists.

tumor growth and metastasis [6, 19, 20].

approaches for cancer treatment.

*4.2.1 G protein-coupled receptor 84*

**signaling**

#### *Self-Renewal Pathways in Acute Myeloid Leukemia Stem Cells DOI: http://dx.doi.org/10.5772/intechopen.94379*

*Acute Leukemias*

LGR4 [5, 6, 19, 20].

**4. Self-renewal signaling in leukemia stem cells**

**4.1 WNT/β-catenin signaling pathway**

Self-renewal is a key property of LSCs and its deregulation is responsible for leukemia initiation and progression, which could be targeted for LSC eradication. Several pathways controlling LSC self-renewal have been identified in AML, such as WNT/β-catenin signaling and G protein-coupled receptors including GPR84 and

β-catenin was first associated with colon cancer almost thirty years ago via its interaction with adenomatous polyposis coli (APC) [21, 22]. It later became evident that the canonical WNT/β-catenin pathway is dysregulated in various cancers, including AML [23, 24]. We and others have demonstrated that aberrant activation of WNT/β-catenin signaling contributes to the transformation of normal HSCs into LSCs [5, 25]. Our studies show that WNT/β-catenin signaling pathway is required for self-renewal of LSCs derived from either normal HSCs or lineage-committed progenitors in AML [5]. The WNT/β-catenin pathway was initially explored in normal HSCs (**Figure 3**). Constitutive activation of β-catenin results in an increase in the number of HSCs *in vitro* [26]. However, *in vivo* studies challenge the *in vitro* observation, where the conditional deletion of β-catenin in adult HSCs does not cause the self-renewal defect in mice [27].

*Schematic diagram of the canonical WNT/*β*-catenin signaling pathway. In the OFF state, defined by the absence of a WNT ligand,* β*-catenin is repressed via a destruction complex composed of APC, scaffold protein Axin, glycogen synthase kinase 3 (GSK3) and casein kinase 1 (CK1) that phosphorylates* β*-catenin leading to its proteasomal degradation [28–30]. In the ON state, a WNT ligand binds to the receptor complex consisting of lipoprotein receptor-related proteins 5 and 6 (LRP5/6) and frizzled receptors (FZD), which recruits the destruction complex, leading to inhibition of* β*-catenin phosphorylation and therefore ensuring nuclear* 

*translocation and the subsequent accumulation of active* β*-catenin [31].*

**100**

**Figure 3.**

On the other hand, several lines of evidence including our own have demonstrated the importance of WNT/β-catenin pathway in regulation of LSC self-renewal in AML [5, 25]. Our studies have shown that deletion of β-catenin impairs LSC function and blocks AML progression in mice [5]. β-catenin can promote leukemogenesis through cooperation with homeobox (HOX) oncoproteins in HSCs [5]. Conversely, lack of endogenous β-catenin in lineage-committed progenitors limits the ability of HOX genes to efficiently transform the progenitor cells [5]. Despite the recognized importance, treatments directly targeting WNT/β-catenin pathway have been elusive, mainly due to our limited understanding of precise mechanisms of the pathway and lack of key druggable molecules involved in driving constitutive activation of the pathway.

Of note, while aberrant activation of β-catenin frequently occurs in human LSCs [25, 32] and is associated with poor patient outcomes in AML [33], increased expression of WNT proteins has not been observed. This suggests that aberrant activation of WNT/β-catenin signaling in AML may require other developmental signaling molecules that function as agonists.

#### **4.2 G protein-coupled receptors serving as modulators of WNT/β-catenin signaling**

G protein-coupled receptors (GPCRs) are a large superfamily of cell surface signaling proteins that bind extracellular ligands to transduce signals into cells via heterotrimeric G proteins [20]. GPCRs can act as modulators of WNT/β-catenin signaling and have a critical role in embryonic development and stem cell maintenance [20, 34, 35]. Dysregulation of GPCRs have detrimental consequences including malignant transformation and have emerged as crucial players in promoting tumor growth and metastasis [6, 19, 20].

The mechanism of action of GPCRs when stimulated by an appropriate ligand (or agonist) is understood in conjunction with its interaction with the G protein heterotrimer, which contains α, β and γ subunits. Ligands binding to GPCRs stimulate conformational changes within the receptor causing the Gα subunit to exchange bound guanosine diphosphate (GDP) for guanosine-5′-triphosphate (GTP). This step is key to the activation of the G protein as it causes the dissociation between the α subunit and the βγ subunit [36]. Each of the G protein subunits is responsible for several downstream effects. The Gα subunits have been classified into four families: Gαs, Gαq, Gαi/o and Gα12/13 each with a distinct function. Typically, Gαs and Gαi moderate cyclic AMP (cAMP) levels by stimulating or inhibiting adenylyl cyclase respectively [37]. Gα<sup>13</sup> typically activates the Rho family of GTPases and Gαq stimulates phospholipase Cβ (PLCβ), leading to activation of intracellular Ca2+ [20]. The βγ dimer subunits activate downstream signaling partners such as Src, phospholipase C, adenylyl cyclase, phosphodiesterases and ion channels [36]. Aberrant activation of GPCRs has a profound effect on many cellular processes and may ultimately lead to malignant progression.

Although therapeutic targeting of GPCR signaling pathways in non-cancer disease is not a new phenomenon, our limited understanding of the role played by these receptors in tumorigenesis has hindered the development of therapeutic approaches for cancer treatment.

#### *4.2.1 G protein-coupled receptor 84*

G protein-coupled receptor 84 (GPR84) is often described as a pro-inflammatory receptor. We have documented a crucial role for GPR84 in sustaining LSC selfrenewal through positive regulation of β-catenin signaling in established AML [19]. Overexpression of GPR84 augments activation of β-catenin and its transcriptional co-factors TCF7L2 and c-FOS, and positively modulates a subset of genes associated with WNT activation and *in vivo* dissemination as well as oncogenic potential of AML cells. On the other hand, GPR84 depletion impairs LSC function and inhibits the development of an aggressive and drug-resistant subtype of AML. The GPR84 deficient phenotype is dependent on β-catenin status as the restoration of β-catenin activation is capable of rescuing the functional defeat [19]. In addition, levels of GPR84 expression are significantly upregulated in human and mouse AML LSCs compared with normal HSCs, thus providing a therapeutic window to selectively target LSCs while sparing normal HSCs [19, 38]. These observations demonstrate a strong rationale for inhibiting GPCR/β-catenin signaling as a novel therapeutic strategy to target drug-resistant malignant stem cells in cancer.

GPR84 is also implicated in pro-inflammatory and fibrotic processes due to its action in macrophages, fibroblasts/myofibroblasts, and epithelial cells [39, 40]. Whilst the precise mechanism of action is unclear, GPR84 antagonist GLPG1205 has been developed to treat idiopathic pulmonary fibrosis patients in a phase II clinical trial (NCT03725852). However, the efficacy of GLPG1205 in AML is yet to be investigated.

#### *4.2.2 Leucine-rich repeat-containing G protein-coupled receptor 4*

Leucine-rich repeat-containing G protein-coupled receptor 4 (LGR4) is another GPCR that we have recently reported to act as a positive modulator of WNT/β-catenin signaling in AML initiation and progression [6]. The cell of origin determines the dependence of LSCs on LGR4 signaling. LSCs derived from HSCs depend primarily on LGR4 signaling for self-renewal and the establishment of an aggressive phenotype in mice; conversely, LSCs derived from lineage-committed progenitors only reveal a partial dependency on LGR4 signaling [6]. LSCs derived from different cellular origins may utilize distinct endogenous signaling mechanisms driving tumorigenesis, where LGR4 in HSC-derived LSCs relays signals via coupling to Gαs to upregulate WNT/ self-renewal target genes but LGR4 in progenitor-derived LSCs signals through Gα<sup>q</sup> to potentiate WNT/β-catenin activation [6, 41]. The origin-dependent difference in pathway requirements contributes to the heterogeneity of an LSC pool within a tumor.

The mechanism underlying the enhanced aggressive leukemia phenotype associated with elevated LGR4 may involve functional cooperation between LGR4 and HOXA9 in LSCs [6]. High level of HOXA9 expression is a characteristic feature of AML, including cases with MLL rearrangements, and is associated with poor patient outcome [42]. Enforced expression of HOXA9/MEIS1 transforms normal HSC-enriched cells where β-catenin is often active, but cannot fully transform committed progenitors that inherently lack β-catenin activity and self-renewal ability [5]. This indicates an indispensable requirement for β-catenin activation in HOXA9 mediated transformation. Consistent with the role of LGR4 as an essential upstream effector of β-catenin signaling, we uncover that LGR4 cooperates with HOXA9/ MEIS1 in HSC-enriched cells contributing to a highly tumorigenic phenotype characteristic of MLL-rearranged AML in mice. Thus, functional cooperation between LGR4 activation and a HOXA9 gene expression program drives LSC self-renewal and leukemogenesis in AML [6].

#### *4.2.3 Therapeutic targeting of LGR4-RSPO3 signaling*

The LGR family members (e.g. LGR4) have been identified as receptors for R-spondin (RSPO) proteins [43]. RSPOs function as WNT agonists [44] that synergize with low levels of WNT to potentiate β-catenin activation [45, 46]. An important feature of RSPOs is their coexpression with and dependence on WNT ligands during mouse development where RSPO expression is reduced by the double knockout of WNT1 and WNT3 [47], and the RSPO activity is inhibited by depletion of WNT3

**103**

**Figure 4.**

*Self-Renewal Pathways in Acute Myeloid Leukemia Stem Cells*

[46, 48] or WNT antagonists (i.e. DKK1) [49]. Although all four RSPO proteins (RSPO1–4) augment WNT/β-catenin signaling, RSPO2 and RSPO3 appear more effective than RSPO1, and RSPO4 is relatively inactive [50]. RSPO3 is prominently expressed in hematopoietic organs [51]. Our study has demonstrated that RSPO2 and RSPO3 can serve as stem cell growth factors to block differentiation and promote proliferation of primary AML patient blasts, and are capable of potentiating β-catenin

*Schematic diagram describing RSPO2/RSPO3-mediated augmentation of the canonical WNT/*β*-catenin* 

*signaling through an LGR4-dependent mechanism in HOXA9-dependent AML [6].*

activation in AML LSCs via an LGR4-dependent mechanism (**Figure 4**) [6].

therapeutic opportunity for selective targeting of AML LSCs.

**5. Limitations of current studies**

The link between RSPO-LGR4 and WNT/β-catenin pathway has opened a new opportunity to specifically target key self-renewal signaling for LSC eradication. We have discovered that RSPO3-LGR4 pathway can be effectively inhibited by a clinicalgrade anti-RSPO3 monoclonal antibody (rosmantuzumab), which disrupts the RSPO3- LGR4 interaction and abrogates leukemia-initiating capacity of patient-derived LSCs without affecting the healthy stem cell compartment [6]. Rosmantuzumab has proven to be safe and well tolerated in Phase I clinical trials conducted on patients with advanced solid tumors [52]. While the therapeutic efficacy of anti-RSPO3 antibody will need further preclinical validation in a large number of patient-derived xenograft models with different mutational profiles, these findings indicate differential dependence of normal and malignant stem cells on RSPO-LGR4 signaling and underline a

As our understanding of cancer continues to grow, we increasingly realize it to be a myriad of heterogenous diseases that defy simple classifications and AML is no exception. As a result, current studies tend to focus on specific tumor markings or specific genes present within tumors. Even within the subgroup of LSCs, there

*DOI: http://dx.doi.org/10.5772/intechopen.94379*

*Self-Renewal Pathways in Acute Myeloid Leukemia Stem Cells DOI: http://dx.doi.org/10.5772/intechopen.94379*

**Figure 4.**

*Acute Leukemias*

with WNT activation and *in vivo* dissemination as well as oncogenic potential of AML cells. On the other hand, GPR84 depletion impairs LSC function and inhibits the development of an aggressive and drug-resistant subtype of AML. The GPR84 deficient phenotype is dependent on β-catenin status as the restoration of β-catenin activation is capable of rescuing the functional defeat [19]. In addition, levels of GPR84 expression are significantly upregulated in human and mouse AML LSCs compared with normal HSCs, thus providing a therapeutic window to selectively target LSCs while sparing normal HSCs [19, 38]. These observations demonstrate a strong rationale for inhibiting GPCR/β-catenin signaling as a novel therapeutic

GPR84 is also implicated in pro-inflammatory and fibrotic processes due to its action in macrophages, fibroblasts/myofibroblasts, and epithelial cells [39, 40]. Whilst the precise mechanism of action is unclear, GPR84 antagonist GLPG1205 has been developed to treat idiopathic pulmonary fibrosis patients in a phase II clinical trial (NCT03725852). However, the efficacy of GLPG1205 in AML is yet to be investigated.

Leucine-rich repeat-containing G protein-coupled receptor 4 (LGR4) is another GPCR that we have recently reported to act as a positive modulator of WNT/β-catenin signaling in AML initiation and progression [6]. The cell of origin determines the dependence of LSCs on LGR4 signaling. LSCs derived from HSCs depend primarily on LGR4 signaling for self-renewal and the establishment of an aggressive phenotype in mice; conversely, LSCs derived from lineage-committed progenitors only reveal a partial dependency on LGR4 signaling [6]. LSCs derived from different cellular origins may utilize distinct endogenous signaling mechanisms driving tumorigenesis, where LGR4 in HSC-derived LSCs relays signals via coupling to Gαs to upregulate WNT/ self-renewal target genes but LGR4 in progenitor-derived LSCs signals through Gα<sup>q</sup> to potentiate WNT/β-catenin activation [6, 41]. The origin-dependent difference in pathway requirements contributes to the heterogeneity of an LSC pool within a tumor. The mechanism underlying the enhanced aggressive leukemia phenotype associated with elevated LGR4 may involve functional cooperation between LGR4 and HOXA9 in LSCs [6]. High level of HOXA9 expression is a characteristic feature of AML, including cases with MLL rearrangements, and is associated with poor patient outcome [42]. Enforced expression of HOXA9/MEIS1 transforms normal HSC-enriched cells where β-catenin is often active, but cannot fully transform committed progenitors that inherently lack β-catenin activity and self-renewal ability [5]. This indicates an indispensable requirement for β-catenin activation in HOXA9 mediated transformation. Consistent with the role of LGR4 as an essential upstream effector of β-catenin signaling, we uncover that LGR4 cooperates with HOXA9/ MEIS1 in HSC-enriched cells contributing to a highly tumorigenic phenotype characteristic of MLL-rearranged AML in mice. Thus, functional cooperation between LGR4 activation and a HOXA9 gene expression program drives LSC self-renewal

strategy to target drug-resistant malignant stem cells in cancer.

*4.2.2 Leucine-rich repeat-containing G protein-coupled receptor 4*

**102**

and leukemogenesis in AML [6].

*4.2.3 Therapeutic targeting of LGR4-RSPO3 signaling*

The LGR family members (e.g. LGR4) have been identified as receptors for R-spondin (RSPO) proteins [43]. RSPOs function as WNT agonists [44] that synergize with low levels of WNT to potentiate β-catenin activation [45, 46]. An important feature of RSPOs is their coexpression with and dependence on WNT ligands during mouse development where RSPO expression is reduced by the double knockout of WNT1 and WNT3 [47], and the RSPO activity is inhibited by depletion of WNT3

*Schematic diagram describing RSPO2/RSPO3-mediated augmentation of the canonical WNT/*β*-catenin signaling through an LGR4-dependent mechanism in HOXA9-dependent AML [6].*

[46, 48] or WNT antagonists (i.e. DKK1) [49]. Although all four RSPO proteins (RSPO1–4) augment WNT/β-catenin signaling, RSPO2 and RSPO3 appear more effective than RSPO1, and RSPO4 is relatively inactive [50]. RSPO3 is prominently expressed in hematopoietic organs [51]. Our study has demonstrated that RSPO2 and RSPO3 can serve as stem cell growth factors to block differentiation and promote proliferation of primary AML patient blasts, and are capable of potentiating β-catenin activation in AML LSCs via an LGR4-dependent mechanism (**Figure 4**) [6].

The link between RSPO-LGR4 and WNT/β-catenin pathway has opened a new opportunity to specifically target key self-renewal signaling for LSC eradication. We have discovered that RSPO3-LGR4 pathway can be effectively inhibited by a clinicalgrade anti-RSPO3 monoclonal antibody (rosmantuzumab), which disrupts the RSPO3- LGR4 interaction and abrogates leukemia-initiating capacity of patient-derived LSCs without affecting the healthy stem cell compartment [6]. Rosmantuzumab has proven to be safe and well tolerated in Phase I clinical trials conducted on patients with advanced solid tumors [52]. While the therapeutic efficacy of anti-RSPO3 antibody will need further preclinical validation in a large number of patient-derived xenograft models with different mutational profiles, these findings indicate differential dependence of normal and malignant stem cells on RSPO-LGR4 signaling and underline a therapeutic opportunity for selective targeting of AML LSCs.

#### **5. Limitations of current studies**

As our understanding of cancer continues to grow, we increasingly realize it to be a myriad of heterogenous diseases that defy simple classifications and AML is no exception. As a result, current studies tend to focus on specific tumor markings or specific genes present within tumors. Even within the subgroup of LSCs, there

exists multiple unique pathways that may work together to achieve a tumorigenic effect. In this regard, the notion of having a single drug to treat AML is archaic. The development of novel therapeutic agents is therefore necessary in order to treat an array of aberrant pathways. Thus, future research must not only focus on the effectiveness of treatment, but also how they relate to specific patient factors.
